Lyell Immunopharma Inc

NASDAQ:LYELUnited States

Lyell Immunopharma, Inc. is a clinical-stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors. The Company is engaged in enrolling a Phase I clinical trial evaluating a ROR1-targeted CAR T-cell therapy in patients with relapsed refractory triple-negative breast cancer and non-small cell lung cancer (NSCLC) and a second Phase I clinical trial evaluating reprogrammed tumor infiltrating lymphocytes (TIL) in patients with advanced melanoma, NSCLC and colorectal cancer. The technologies powering its product candidates are designed to address barriers that limit consistent and long-lasting responses to cell therapy for solid tumors: T-cell exhaustion and lack of durable stemness, which includes the ability to persist and self-renew to drive durable tumor cytotoxicity. The Company is applying its proprietary ex vivo genetic and epigenetic reprogramming technologies to address these barriers in order to develop medicines.

Contact Information

Headquarters

201 Haskins Way, Suite 301SOUTH SAN FRANCISCO, CA, United States 94080

Phone

650-695-0677

Fax

302-531-3150

Executives

Chairman of the Board

Richard Klausner

President, Chief Executive Officer, Director

Lynn Seely

Chief Financial Officer

Charles Newton

Chief Operating Officer

Stephen Hill

Chief Scientific Officer

Gary Lee